Availability of totally implantable venous access devices in cancer patients is high in the long term: a seven-year follow-up study
dc.contributor.author | Tumay, Latif Volkan | |
dc.contributor.author | Guner, Osman Serhat | |
dc.date.accessioned | 2023-02-21T12:34:35Z | |
dc.date.available | 2023-02-21T12:34:35Z | |
dc.date.issued | 2021-01-01 | |
dc.description.abstract | Purpose Totally implantable venous access devices (TIVADs) currently have an important place in medical oncology practice | |
dc.description.abstract | however, their long-term availability deserves further investigation, since they are usually required by patients for prolonged periods. This study aimed to evaluate long-term availability of TIVADs in adult cancer patients, in conjunction with complication/removal rates over time and associated risk factors during 7-year follow-up. Methods A total of 204 adult cancer patients who underwent TIVAD placement via subclavian vein using the Seldinger technique were included in this study. Medical data and catheter follow-up records were investigated retrospectively. Complications and port removals due to complications were evaluated over time. Results During median 21.9 (range, 0.7-82.9) months of follow-up, great majority of the patients did not require catheter removal due to complications (91.7\%). During a total follow-up of 183,328 catheter days, 20 (9.8\%) patients had complications with an incidence of 0.109 cases per 1000 catheter days and 18 (8.8\%) of them required TIVAD removal (0.098 cases per 1000 catheter days). Most device removals due to complications (15/18, 83.3\%) occurred within the first 24 months. Multivariate analysis identified left-sided device location as the only significant independent predictor of short device availability (OR, 3.5 {[}95\% CI, 1.1-11.1], p = 0.036). Conclusion TIVADs in cancer patients appear to be safe and their availability appears to be high in the long term. A decision for early removal might be revisited. Opting for the accustomed side (right side in the present study) for implantations seems to be associated with better outcomes. | |
dc.description.issue | 7 | |
dc.description.issue | JUL | |
dc.description.pages | 3531-3538 | |
dc.description.volume | 29 | |
dc.identifier.doi | 10.1007/s00520-020-05871-6 | |
dc.identifier.uri | https://hdl.handle.net/11443/1772 | |
dc.identifier.uri | http://dx.doi.org/10.1007/s00520-020-05871-6 | |
dc.identifier.wos | WOS:000587148100002 | |
dc.publisher | SPRINGER | |
dc.relation.ispartof | SUPPORTIVE CARE IN CANCER | |
dc.subject | Totally implantable venous access devices (TIVAD) | |
dc.subject | Vascular access devices | |
dc.subject | Long-term availability | |
dc.subject | Catheter-related complications | |
dc.subject | Malignancy | |
dc.subject | Quality of life | |
dc.title | Availability of totally implantable venous access devices in cancer patients is high in the long term: a seven-year follow-up study | |
dc.type | Article |